ReShape Lifesciences (NASDAQ:RSLS) Posts Quarterly Earnings Results

ReShape Lifesciences (NASDAQ:RSLS) posted its quarterly earnings data on Friday. The medical device company reported ($1.89) EPS for the quarter, Zacks reports. ReShape Lifesciences had a negative return on equity of 179.83% and a negative net margin of 86.36%.

ReShape Lifesciences Trading Up 21.1 %

RSLS opened at $0.46 on Friday. ReShape Lifesciences has a twelve month low of $0.34 and a twelve month high of $29.00. The company has a fifty day moving average of $1.59 and a 200-day moving average of $4.02.

ReShape Lifesciences Company Profile

ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.